The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD). A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD. The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens. RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.

中文翻译：

---

新生血管性年龄相关性黄斑变性治疗模式的演变：现实世界证据的回顾

这项工作的目的是评估现实世界证据 (RWE) 在改变抗血管内皮生长因子 (VEGF) 治疗实践和改善新生血管性年龄相关性黄斑变性 (nAMD) 现实世界治疗策略方面的贡献。我们进行了 PubMed 文献检索，以回顾大量英语研究，这些研究旨在调查可用于 nAMD 的抗 VEGF（阿柏西普和雷珠单抗）治疗范例的现实有效性。回顾了抗 VEGF 治疗 nAMD 的 pro re nata (PRN)、治疗和延长 (T&E) 和固定双月给药方案的证据，并总结了结果。RWE 证明，与固定剂量和 PRN 方案相比，T&E 方案可以优化视觉效果，同时减轻患者、诊所和医生的负担。RWE 帮助开发和改进了 nAMD 的实际治疗策略，旨在优化视觉效果并减轻临床实践中的治疗负担。在各种方案中，T&E 方案最有可能充分平衡 nAMD 患者的临床结果和治疗负担。